ISB-1442 is under clinical development by Ichnos Sciences and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISB-1442’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISB-1442 is under development for the treatment of relapsed/refractory multiple myeloma, acute myeloid leukemia. It acts by targeting CD38 and CD47.The drug candidate is developed based on BEAT (Bi-specific Engagement by Antibodies based on the T cell receptor) platform. It is a new biological entity (NBE). It is administered through subcutaneous route.
Ichnos Sciences overview
Ichnos Sciences is a bio pharmaceutical manufacturing company. The company is engaged in developing therapies for treating oncology and autoimmune disease. It’s technology portfolio includes BEAT (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform which uses a novel method for engineering bispecific antibodies that may treat cancers and ISB 830 is designed to block the key immune system activation factor to treat a variety of illnesses and provides an entirely novel method of action for the treatment of autoimmune disease. Ichnos Sciences is headquartered in New York, the US.
For a complete picture of ISB-1442’s drug-specific PTSR and LoA scores, buy the report here.